RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 PDE-5 Inhibition Has No Effect on Measures of Heart Failure
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 2
SP 19
OP 19
DO 10.1177/155989771302010
UL http://mdc.sagepub.com/content/13/2/19.1.abstract
AB The phosphodiesterase type 5 (PDE-5) inhibitor sildenafil failed to improve peak exercise capacity in patients with diastolic heart failure (HF) in a double-blind, placebo-controlled, randomized clinical trial. Results from the Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure trial [RELAX; Redfield MM et al. JAMA 2013] did not replicate the cardiovascular benefits of PDE-5 inhibition obtained in studies of experimental HF and small clinical studies.